Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more

Location: 1 Enterprise Drive, Shelton, CT, 06484-4779, United States | Website: https://www.intensitytherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

8.683M

52 Wk Range

$0.26 - $5.09

Previous Close

$0.32

Open

$0.31

Volume

7,773,047

Day Range

$0.30 - $0.34

Enterprise Value

4.85M

Cash

929K

Avg Qtr Burn

-3.211M

Insider Ownership

23.59%

Institutional Own.

9.99%

Qtr Updated

03/31/25